Featured News

 

Latest News

Reversing Gene Damage to Treat Blindness
Reversing Gene Damage to Treat Blindness
News   Apr 24, 2017

n mouse models, advanced gene editing tool reprogrammed photoreceptor rods to mutation-resistant cones.

READ MORE

Malaria Parasite Protein Shows Promise as Cancer Therapeutic
Malaria Parasite Protein Shows Promise as Cancer Therapeutic
News   Apr 21, 2017

A drug created from a malaria protein stopped tumour growth of chemotherapy-resistant bladder cancer, offering hope for cancer patients not responding to standard treatments.

READ MORE

How Cancer Evades the Immune System
How Cancer Evades the Immune System
News   Apr 21, 2017

A team of scientists from Singapore has discovered new ways in which cancers can escape the body’s immune system.

READ MORE

Synpromics Raise £5.2m in its Latest Fundraising Round
Synpromics Raise £5.2m in its Latest Fundraising Round
News   Apr 20, 2017

Synpromics, a leading synthetic promoter and gene control company has raised £5.2m in its latest funding round.

READ MORE

Agilent Technologies Presents Thought Leader Award to Professor Dwight Stoll for Separation Science Research
Agilent Technologies Presents Thought Leader Award to Professor Dwight Stoll for Separation Science Research
News   Apr 20, 2017

Prof. Stoll receives the award in support of his research, applying two-dimensional liquid chromatography (2D-LC) to biopharmaceutical analysis.

READ MORE

FDA Approves Pembrolizumab for Hodgkin Lymphoma
FDA Approves Pembrolizumab for Hodgkin Lymphoma
News   Apr 20, 2017

On March 14, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) for the treatment of some patients with classical Hodgkin lymphoma (cHL).

READ MORE

The Next Generation of Pancreatic Cancer Therapeutics
The Next Generation of Pancreatic Cancer Therapeutics
News   Apr 20, 2017

Currently, there are not many effective therapies available other than surgery, and that is not an option for many patients.

READ MORE

Synpromics Raises £5.2m of New Investment
Synpromics Raises £5.2m of New Investment
News   Apr 20, 2017

The majority of the new investment will be used to further develop and exemplify Synpromics proprietary PromPT™ synthetic promoter design platform.

READ MORE

New Version of CRISPR Successfully Repairs Defects in Duchenne Muscular Dystrophy
New Version of CRISPR Successfully Repairs Defects in Duchenne Muscular Dystrophy
News   Apr 18, 2017

Using the new gene-editing enzyme CRISPR-Cpf1, researchers at UT Southwestern Medical Center have successfully corrected Duchenne muscular dystrophy in human cells and mice in the lab.

READ MORE

Resident Memory T Cells Protect Against Future Cancers
Resident Memory T Cells Protect Against Future Cancers
News   Apr 18, 2017

Researchers find that cancer-fighting T cells reside in the skin, where they can rapidly respond to kill melanoma cells and serve a critical role in protecting against future tumors.

READ MORE